N-(3-(2-(2-chloropyriMidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonaMide

Base Information

• Chemical Name: N-(3-(2-(2-chloropyriMidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonaMide
• CAS No.: 1195768-20-7
• Molecular Formula: C18H11ClF3N3O3S
• Molecular Weight: 441.818
• Mol file: 1195768-20-7.mol

Synonyms:N-(3-(2-(2-chloropyriMidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonaMide

Chemical Property of N-(3-(2-(2-chloropyriMidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonaMide

Chemical Property:

• Boiling Point: 609.2±65.0 °C(Predicted)
• PKA: 6.61±0.10(Predicted)
• PSA: 97.40000
• Density: 1.567±0.06 g/cm3(Predicted)
• LogP: 4.92730

Purity/Quality:

99% ^*data from raw suppliers

N-{3-[2-(2-Chloropyrimidin-4-yl)acetyl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide 95+% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

Technology Process of N-(3-(2-(2-chloropyriMidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonaMide

There total 10 articles about N-(3-(2-(2-chloropyriMidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonaMide which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 82.0%

2-chloro-4-methylpyrimidine (13036-57-2) + 3-(2,6-difluorobenzenesulfonamido)-2-fluorobenzoic acid methyl ester (1195768-19-4) → N-(3-(2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide (1195768-20-7)

Guidance literature:

3-(2,6-difluorobenzenesulfonamido)-2-fluorobenzoic acid methyl ester; With lithium hexamethyldisilazane; In tetrahydrofuran; at 0 ℃; for 0.166667h;

2-chloro-4-methylpyrimidine; In tetrahydrofuran; at 0 - 20 ℃; for 2h;

Reference yield:

2,6-difluorobenzene-1-sulfonyl chloride (60230-36-6) → N-(3-(2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide (1195768-20-7)

Guidance literature:

Multi-step reaction with 2 steps

1: pyridine / dichloromethane / 15 - 25 °C

2: lithium hexamethyldisilazane / tetrahydrofuran / 1 h / 0 - 3 °C

With pyridine; lithium hexamethyldisilazane; In tetrahydrofuran; dichloromethane;

Reference yield:

2-fluoro-3-bromobenzoic acid methyl ester (206551-41-9) → N-(3-(2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide (1195768-20-7)

Guidance literature:

Multi-step reaction with 4 steps

1: tris(dibenzylideneacetone)dipalladium⁽⁰⁾ chloroform complex; 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; caesium carbonate / 90 °C / Sealed tube; Inert atmosphere

2: trifluoroacetic acid / dichloromethane / 1 h / 20 °C

3: pyridine / dichloromethane / 20 °C

4: lithium hexamethyldisilazane / tetrahydrofuran / 1 h / 20 °C / Cooling with ice

With pyridine; tris(dibenzylideneacetone)dipalladium⁽⁰⁾ chloroform complex; caesium carbonate; 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; trifluoroacetic acid; lithium hexamethyldisilazane; In tetrahydrofuran; dichloromethane;

DOI:10.1021/ml4000063

upstream raw materials:

2-chloro-4-methylpyrimidine

3-(2,6-difluorobenzenesulfonamido)-2-fluorobenzoic acid methyl ester

3-amino-2-fluoro benzoic acid

2,6-difluorobenzene-1-sulfonyl chloride

Downstream raw materials:

N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1 ,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide

N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(tetrahydro-2H-pyran-4-yl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide

N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonic acid

dabrafenib

Refernces

• 1、 -. "LIM KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN LIMK-MEDIATED DISEASES". Page/Page column 36. . Retrieved 2018/04/20.
• 2、 -. "PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER". Page/Page column 30. . Retrieved 2017/03/21.